Grocery Aisle Vitamin Stuns Cancer Docs

Assorted dietary supplements on wooden spoons — Photo: 1989studio / Shutterstock

A cheap vitamin that sits in every grocery store may help people with a blood condition that can turn into cancer live longer.

Quick Take

A phase 2 trial called EVITA tested daily oral vitamin C in 109 patients with precancerous blood disorders or early-stage blood cancer.
Vitamin C did not change the trial’s main goal, which was slowing abnormal blood cell growth.
Patients taking vitamin C had fewer side effects and showed a surprising survival edge over nearly three years.
Doctors say the finding is promising but needs a bigger study before it changes how patients are treated.

What The Trial Actually Tested

Researchers in Denmark and the United States ran a randomized, double-blind, placebo-controlled study called EVITA. It enrolled 109 adults with clonal cytopenia of undetermined significance or low-risk myeloid blood cancers, conditions that can quietly progress toward leukemia. Half the group took 1,000 milligrams of oral vitamin C daily for one year. The other half took a placebo. Neither doctors nor patients knew who got which.

The science behind the idea is not new. Vitamin C helps activate TET enzymes, proteins that control which genes switch on or off inside blood-forming cells. Scientists have long suspected that boosting TET activity might calm down the faulty cell clones that cause these disorders before they turn cancerous. That theory is why the trial focused on clonal progression as its main measuring stick.

The Main Goal Came Up Empty

On that main measuring stick, vitamin C did not deliver. The supplement failed to slow or stop the abnormal blood cell clones from growing, which was the trial’s primary endpoint. Researchers were candid about this result rather than dressing it up. The study simply did not prove vitamin C changes the underlying disease biology it was designed to target.

That kind of outcome often ends a story in medical research. But EVITA kept researchers’ attention because of what happened everywhere else in the data. Patients taking vitamin C experienced noticeably fewer adverse events during the yearlong treatment period and the follow-up that came after it. Fewer complications is not a minor detail for people already managing a fragile blood condition.

The Survival Signal That Surprised Everyone

The bigger surprise showed up when researchers looked at survival. Patients who took vitamin C were significantly more likely to be alive after almost three years of follow-up compared with those who got the placebo. This was an exploratory analysis, meaning it was not the question the trial was originally built to answer, but the gap between groups was wide enough to turn heads in the oncology community.

Independent experts reviewing the results called the trial well designed and said the press coverage reflected the science accurately. One reviewer noted the survival improvement was unexpected and worth taking seriously, even while cautioning that it came from a secondary analysis rather than the trial’s confirmed goal. That distinction matters, and it is the honest, full picture here.

Why Phase 2 Results Deserve Respect, Not Hype

Phase 2 trials exist to generate hypotheses, not settle them. A negative primary endpoint paired with a strong secondary signal is a familiar pattern in cancer research, and it typically points toward a larger confirmatory trial rather than an immediate change in treatment guidelines. Methodologists have warned for years that secondary results should never substitute for a trial’s main finding, no matter how encouraging they look on paper.

Still, dismissing this result outright would ignore real evidence from a rigorously controlled study. Vitamin C is inexpensive, widely available, and carries a well-known safety profile, which makes a larger follow-up trial a reasonable and low-risk next step. Patients and doctors deserve a clear-eyed answer, not years of silence while bureaucratic funding committees debate priorities.

What Comes Next For Patients And Doctors

The EVITA findings, published in the journal Cancer, give patients with these blood disorders a reason for cautious hope without overselling a cure. Nothing here suggests patients should abandon standard monitoring or treatment plans in favor of vitamin supplements alone. What it does suggest is that an everyday vitamin, already sitting in most American medicine cabinets, may be worth serious further study in a disease space that has few easy answers.

Research teams at the Van Andel Institute and partner hospitals say larger trials are the logical next step to confirm the survival signal. Until then, the honest takeaway is simple: vitamin C did not do what scientists originally hoped, but it did something else that might matter even more.